Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial-Reference-Cited by-同舟云学术

Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial

Published:2011-04-05 Issue:3 Volume:18 Page:203-212
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Xu Binghe,Jiang Zefei,Kim Sung-Bae,Yu Shiying,Feng Jifeng,Malzyner Artur,del Giglio Auro,Chung Hyun C.,Shen Li Jun,Pen Daniel Lee Kay

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12282-011-0260-y.pdf

Reference37 articles.

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

2. Colozza M, de Azambuja E, Personeni N, Lebrun F, Picart M, Cardoso F. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist. 2007;12:253–70.

3. O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–9.

4. Cardoso F, Bedard P, Winer E, Paganini O, Senkus-Konefka E, Fallowfield L, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101:1174–81.

5. Jassem J, Carroll C, Ward S, Simpson E, Hind D. The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. Eur J Cancer. 2009;45:2749–58.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis;Cancer Pathogenesis and Therapy;2023-06

2. Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison;Clinical Breast Cancer;2023-04

3. A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer;Therapeutic Advances in Medical Oncology;2022-01

4. Platinum-containing regimens for triple-negative metastatic breast cancer;Cochrane Database of Systematic Reviews;2020-10-21

5. Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles;Clinical Breast Cancer;2019-04